AGN Receives Notice of Allowance for its Lead CDK Drug More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it.
AGN.c AGNPF a Canadian clinical stage pharmaceutical development company just announced they received a Notice of Allowance from the United States Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast).
Repirinast is AGN’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% and reduced the NAFLD score, a composite histopathological measure of inflammation, steatosis and ballooning, by 31%.
AGN’s intellectual property strategy includes protecting its compounds by filing patent applications including method of use, dosing, and formulations, and for new composition of matter patents based on novel salt forms.
https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/181/algernon-pharmaceuticals-announces-notice-of-allowance-for